PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-2307
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma ; day:24 ; month:1 ; year:2020 ; pages:1-9
Virchows Archiv ; (24.1.2020), 1-9
- Creator
-
Martin de la Fuente, Laura
Westbom-Fremer, Sofia
Arildsen, Nicolai Skovbjerg
Hartman, Linda
Malander, Susanne
Kannisto, Päivi
Måsbäck, Anna
Hedenfalk, Ingrid
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00428-020-02751-6
- URN
-
urn:nbn:de:101:1-2020041901222910397217
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Martin de la Fuente, Laura
- Westbom-Fremer, Sofia
- Arildsen, Nicolai Skovbjerg
- Hartman, Linda
- Malander, Susanne
- Kannisto, Päivi
- Måsbäck, Anna
- Hedenfalk, Ingrid
- SpringerLink (Online service)
Other Objects (12)
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors
Prognostic value of immunohistochemical expression of PD-1 and PD-L1 on tumor cells and tumor-infiltrating stromal immune cells in primary breast cancer
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors
Prognostic value of immunohistochemical expression of PD-1 and PD-L1 on tumor cells and tumor-infiltrating stromal immune cells in primary breast cancer
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors
Tumor-infiltrating CD45RO+ Memory T Lymphocytes Predict Favorable Clinical Outcome in Solid Tumors
Prognostic value of immunohistochemical expression of PD-1 and PD-L1 on tumor cells and tumor-infiltrating stromal immune cells in primary breast cancer
IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer